XML 50 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Schedule Of Share Based Compensation Restricted Stock Awards Stock Options And Stock Appreciation Rights
The table below summarizes the stock-based compensation expense activity recognized during the following periods:

Three Months Ended March 31,
20222021
(In thousands)
Recognized stock compensation expense$1,038 $— 
Capitalized stock compensation cost for our oil and natural gas properties
— — 
Tax benefit on stock-based compensation$254 $— 
Schedule of Nonvested Restricted Stock Units Activity The table below summarizes the activity pertaining to nonvested RSUs during the three months ended March 31, 2022:
Three Months Ended March 31,
2022
Number
of Shares
Weighted
Average Grant Date
Fair Value
Nonvested RSUs, beginning of period315,529 $26.71 
Granted (1)
7,850 30.50 
Vested(524)30.50 
Forfeited— — 
Nonvested RSUs, end of period (2)
322,855 $26.80 
1.RSUs were granted on January 7, 2022 with an aggregate grant date fair value of $0.2 million and will vest equally each month for thirty months.
2.The aggregate compensation cost related to nonvested RSUs not yet recognized as of March 31, 2022 was $7.5 million with a weighted average remaining service period of 1.4 years.
Share-based Payment Arrangement, Option, Activity The table below summarizes the activity pertaining to outstanding stock options during the three months ended March 31, 2022:
Three Months Ended March 31,
2022
Number
of Shares
Weighted Average
Exercise Price
Outstanding stock options, beginning of period361,418 $45.00 
Granted (1)
13,416 45.00 
Exercised— — 
Forfeited or expired— — 
Outstanding stock options, end of period (2)
374,834 $45.00 
1.Stock options were granted on January 7, 2022 with an aggregate grant date fair value of $0.1 million and will 100% vest on the first anniversary of the grant date.
2.The stock options outstanding as of March 31, 2022 had a weighted average remaining contractual term of 4.5 years and an aggregate intrinsic value of $6.2 million. None of the stock options outstanding as of March 31, 2022 were exercisable. The aggregate compensation cost related to outstanding options not yet recognized as of March 31, 2022 was $3.5 million with a weighted average remaining service period of 1.5 years.